New scenarios in Vacuoles, E1 enzyme, X linked, Autoinflammatory, Somatic (VEXAS) syndrome: Evolution from myelodysplastic syndrome to acute myeloid leukemia

Affiliations

¹ Hematology and Bone Marrow Transplantation Unit, Federico II University of Naples, Hematology Department, Naples, Italy; Department of Clinical Medicine and Surgery, Hematology Unit, University Federico II, Naples, Italy. Electronic address: giorgia.battipaglia@unina.it.
² Hematology and Bone Marrow Transplantation Unit, Federico II University of Naples, Hematology Department, Naples, Italy.
³ Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
⁴ Hematology and Bone Marrow Transplantation Unit, Federico II University of Naples, Hematology Department, Naples, Italy; Department of Clinical Medicine and Surgery, Hematology Unit, University Federico II, Naples, Italy.
⁵ Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
⁶ Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Torino), Italy.
⁷ Centre for Advanced Biotechnology (CEINGE), Naples, Italy.
⁸ Centre for Advanced Biotechnology (CEINGE), Naples, Italy; Department of Molecular Medicine and Medical Biotechnologies, University Federico II and Centre for Advanced Biotechnology (CEINGE), Naples, Italy.

Giorgia Battipaglia et al. Curr Res Transl Med. 2023 Apr-Jun.

. 2023 Apr-Jun;71(2):103386.

doi: 10.1016/j.retram.2023.103386. Epub 2023 Feb 26.

¹ Hematology and Bone Marrow Transplantation Unit, Federico II University of Naples, Hematology Department, Naples, Italy; Department of Clinical Medicine and Surgery, Hematology Unit, University Federico II, Naples, Italy. Electronic address: giorgia.battipaglia@unina.it.
² Hematology and Bone Marrow Transplantation Unit, Federico II University of Naples, Hematology Department, Naples, Italy.
³ Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy.
⁴ Hematology and Bone Marrow Transplantation Unit, Federico II University of Naples, Hematology Department, Naples, Italy; Department of Clinical Medicine and Surgery, Hematology Unit, University Federico II, Naples, Italy.
⁵ Department of Biomedicine and Prevention, University of Rome Tor Vergata, Rome, Italy; Department of Translational Hematology and Oncology Research, Taussig Cancer Institute, Cleveland Clinic, Cleveland, OH, USA.
⁶ Medical Oncology, Candiolo Cancer Institute, FPO-IRCCS, Candiolo (Torino), Italy.
⁷ Centre for Advanced Biotechnology (CEINGE), Naples, Italy.
⁸ Centre for Advanced Biotechnology (CEINGE), Naples, Italy; Department of Molecular Medicine and Medical Biotechnologies, University Federico II and Centre for Advanced Biotechnology (CEINGE), Naples, Italy.

No abstract available

Keywords: Acute myeloid leukemia; Myelodysplastic syndrome; VEXAS; Venetoclax.

Conflict of interest statement

Competing interests Authors have no conflicts of interest to declare.